
Pharmacally
Ziftomenib
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Ziftomenib
Clinical TrialsKura Oncology and Kyowa Kirin Report Updated Frontline Data from KOMET-007 Trial of Ziftomenib in NPM1-m or KMT2A-r AMLUpdated frontline KOMET-007 results showed CRc rates of 96% in NPM1-mutant AML and 90% in KMT2A-rearranged AML, with high MRD negativity and a manageable safety profile for ziftomenib…Fact-Checked
Clinical TrialsKyowa Kirin, Kura Oncology Dose First Patient in Japan Ziftomenib StudyKura Oncology Kyowa Kirin and Kura Oncology initiate a Japanese Phase 2 trial of ziftomenib in relapsed or refractory NPM1-mutated…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.